Navigation Links
PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
Date:7/16/2008

BOSTON, July 16 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, announced today that it has promoted Mark A. Goldberg, M.D., to Chief Operating Officer (COO). Dr. Goldberg previously served as President of Clinical Research Services and Perceptive Informatics at PAREXEL. He will continue to oversee these areas of the Company and report to Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL.

"Dr. Goldberg has been an asset to PAREXEL's executive management team for more than 11 years. His appointment as COO is in recognition of his strong leadership skills and increasing responsibilities, especially as we have expanded our clinical development capabilities and global footprint, including the recent extension of our capabilities in the Asia-Pacific region," said Mr. von Rickenbach. "Dr. Goldberg has led the strong performance in Clinical Research Services, our largest business segment, and has helped to build Perceptive Informatics into a leading provider of advanced technologies that facilitate the clinical development process. We look forward to his continued contributions in meeting our operational and financial goals, and solidifying our position as a global leader in full service clinical development."

Dr. Goldberg stated, "In this role, I look forward to working with our global management team to capitalize on the strong market opportunity for global biopharmaceutical services. My focus will include further strengthening our client relationships, as well as leveraging PAREXEL's leadership role in the convergence of services and technology in support of clinical research."

Dr. Goldberg's combined medical, technic
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
3. PAREXEL Expands Global Clinical Logistics Capabilities
4. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
5. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
6. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
7. PAREXEL Reaches Agreement To Acquire ClinPhone
8. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
9. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
10. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
11. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... the fourth in a series of articles on developing start-up companies ... Madison, Wis. - In my last column for Stage 3, ... In the meantime, I received a thoughtful response about the ... column, dated November 17, 2006, discussed naming the entity. ...
... too many worries right now. As the CEO of ... dominates classified advertising, he leads a company that continues ... of a housing discrimination lawsuit filed against Craigslist in ... deal with. , ,But Buckmaster, who is given much ...
... Wis. - Sonic Foundry, Inc. has ... common stock in which it raised $11.25 million for ... 21 the offering of common stock at $3.75 per ... previously filed with the Securities and Exchange Commission ...
Cached Biology Technology:Early Stage, Step 4: Cautionary trademark tales 2Early Stage, Step 4: Cautionary trademark tales 3Craigslist exec strives to keep the Internet neutral 2Craigslist exec strives to keep the Internet neutral 3Craigslist exec strives to keep the Internet neutral 4
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... HOLE, MATiny, toxic protein particles severely disrupt neurotransmission and ... separate studies by Marine Biological Laboratory (MBL) researchers have ... beta, which has long been known to accumulate and ... "These small particles that haven,t aggregated into plaquesthese ...
... A University of Florida scientist whose interest in ... molecular building blocks that shape appendages ranging from feet ... Early Career Scientist today (Thursday, March 26), a distinction ... Martin Cohn, a developmental biologist and a member ...
... A material developed at the Hebrew University of ... following surgery has led to approval by the U.S. ... use in pediatric cardiac surgery patients. The ... of novel, tailor-made, biodegradable polymers for the prevention of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3Hebrew University professor's work leads to FDA approval for product 2